ASCO 2024 | Linvoseltamab versus teclistamab for TCE RRMM and the sequencing of bispecifics with CAR-Ts
Sundar Jagannath
• 3 Jun 2024
Sundar Jagannath, MD, Tisch Cancer Institute at Mount Sinai, New York, NY, discusses an indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). The comparison showed that linvoseltamab had better overall response rates (ORR), complete response (CR) rates, progression-free survival (PFS), and time-to-next treatment (TTNT). Dr Jagannath also discusses sequencing bispecific antibodies with CAR T-cells. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
